Dapoxetine, a novel treatment for premature ejaculation, does not have pharmacokinetic interactions with phosphodiesterase-5 inhibitors

@article{Dresser2006DapoxetineAN,
  title={Dapoxetine, a novel treatment for premature ejaculation, does not have pharmacokinetic interactions with phosphodiesterase-5 inhibitors},
  author={Mark J. Dresser and Dhaval G Desai and Shalini Gidwani and Allen D. Seftel and Nishit B Modi},
  journal={International Journal of Impotence Research},
  year={2006},
  volume={18},
  pages={104-110}
}
Potential pharmacokinetic interactions between dapoxetine, a serotonin transporter inhibitor developed for the treatment of premature ejaculation (PE), and the phosphodiesterase-5 inhibitors tadalafil and sildenafil, agents used in the treatment of erectile dysfunction (ED), were investigated in an open-label, randomized, crossover study (n=24 men) comparing dapoxetine 60 mg, dapoxetine 60 mg+tadalafil 20 mg, and dapoxetine 60 mg+sildenafil 100 mg. Plasma concentrations of dapoxetine, tadalafil… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 24 extracted citations

Emerging and investigational drugs for premature ejaculation

Translational andrology and urology • 2016
View 1 Excerpt

The office management of ejaculatory disorders

Translational andrology and urology • 2016
View 1 Excerpt

References

Publications referenced by this paper.
Showing 1-10 of 23 references

Men with both premature ejaculation (PE) and erectile dysfunction (ED) experience lower quality of life than men with either PE or ED alone. Presented at the World Congress of Sexology

R Shabsigh, MA Perelman
July 10–15, • 2005

Similar Papers

Loading similar papers…